TWI845479B - 增強及/或穩定Fabry氏症患者之心臟功能之方法 - Google Patents

增強及/或穩定Fabry氏症患者之心臟功能之方法 Download PDF

Info

Publication number
TWI845479B
TWI845479B TW107129901A TW107129901A TWI845479B TW I845479 B TWI845479 B TW I845479B TW 107129901 A TW107129901 A TW 107129901A TW 107129901 A TW107129901 A TW 107129901A TW I845479 B TWI845479 B TW I845479B
Authority
TW
Taiwan
Prior art keywords
migalastat
patient
mwfs
patients
ert
Prior art date
Application number
TW107129901A
Other languages
English (en)
Chinese (zh)
Other versions
TW201919619A (zh
Inventor
傑夫 卡斯特利
傑 巴斯
妮娜 史庫班
Original Assignee
美商阿米庫斯醫療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI845479(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商阿米庫斯醫療股份有限公司 filed Critical 美商阿米庫斯醫療股份有限公司
Publication of TW201919619A publication Critical patent/TW201919619A/zh
Application granted granted Critical
Publication of TWI845479B publication Critical patent/TWI845479B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW107129901A 2017-08-28 2018-08-28 增強及/或穩定Fabry氏症患者之心臟功能之方法 TWI845479B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
US62/550,984 2017-08-28

Publications (2)

Publication Number Publication Date
TW201919619A TW201919619A (zh) 2019-06-01
TWI845479B true TWI845479B (zh) 2024-06-21

Family

ID=63528948

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107129901A TWI845479B (zh) 2017-08-28 2018-08-28 增強及/或穩定Fabry氏症患者之心臟功能之方法

Country Status (26)

Country Link
US (1) US20200222377A1 (enExample)
EP (3) EP3675853B1 (enExample)
JP (3) JP7755929B2 (enExample)
KR (2) KR102790184B1 (enExample)
CN (1) CN111770753A (enExample)
AR (1) AR112482A1 (enExample)
AU (2) AU2018326364B2 (enExample)
CA (1) CA3074450C (enExample)
CL (1) CL2020000491A1 (enExample)
DK (2) DK4176877T3 (enExample)
EA (1) EA202090564A1 (enExample)
ES (2) ES2931054T3 (enExample)
FI (1) FI4176877T3 (enExample)
HR (2) HRP20250064T1 (enExample)
HU (2) HUE070433T2 (enExample)
IL (3) IL272893B2 (enExample)
LT (2) LT4176877T (enExample)
MX (2) MX2020002229A (enExample)
PL (2) PL4176877T3 (enExample)
PT (2) PT4176877T (enExample)
RS (2) RS66515B1 (enExample)
SG (1) SG11202001707PA (enExample)
SI (1) SI4176877T1 (enExample)
SM (2) SMT202500073T1 (enExample)
TW (1) TWI845479B (enExample)
WO (1) WO2019046244A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) * 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
US10811814B2 (en) 2017-08-28 2020-10-20 John Mezzalingua Associates, LLC Weather protecting (WP) housing for coaxial cable connectors

Also Published As

Publication number Publication date
IL272893B2 (en) 2024-07-01
CN111770753A (zh) 2020-10-13
HUE060287T2 (hu) 2023-02-28
SG11202001707PA (en) 2020-03-30
HUE070433T2 (hu) 2025-06-28
FI4176877T3 (fi) 2025-03-06
PT3675853T (pt) 2022-11-28
PL4176877T3 (pl) 2025-04-07
EP4176877B1 (en) 2024-12-04
CL2020000491A1 (es) 2020-09-11
EP4176877A1 (en) 2023-05-10
CA3074450C (en) 2024-10-01
DK3675853T3 (da) 2022-11-28
IL310648A (en) 2024-04-01
WO2019046244A1 (en) 2019-03-07
EP3675853B1 (en) 2022-09-07
RS63742B1 (sr) 2022-12-30
SMT202200459T1 (it) 2023-01-13
RS66515B1 (sr) 2025-03-31
JP7755929B2 (ja) 2025-10-17
BR112020003974A2 (pt) 2020-09-01
IL272893B1 (en) 2024-03-01
EP4588476A1 (en) 2025-07-23
IL324182A (en) 2025-12-01
EA202090564A1 (ru) 2020-06-15
KR20200044908A (ko) 2020-04-29
TW201919619A (zh) 2019-06-01
DK4176877T3 (da) 2025-02-24
IL272893A (en) 2020-04-30
SI4176877T1 (sl) 2025-03-31
CA3074450A1 (en) 2019-03-07
KR20250049561A (ko) 2025-04-11
KR102790184B1 (ko) 2025-04-01
HRP20221366T1 (hr) 2023-01-06
PL3675853T3 (pl) 2022-12-27
EP3675853A1 (en) 2020-07-08
HRP20250064T1 (hr) 2025-03-14
PT4176877T (pt) 2025-02-24
JP2020531550A (ja) 2020-11-05
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
US20200222377A1 (en) 2020-07-16
ES3013820T3 (en) 2025-04-15
LT4176877T (lt) 2025-02-10
MX2020002229A (es) 2020-07-20
AU2024266945A1 (en) 2024-12-19
JP2025138638A (ja) 2025-09-25
AU2018326364A1 (en) 2020-04-09
LT3675853T (lt) 2022-12-12
JP2023051998A (ja) 2023-04-11
AU2018326364B2 (en) 2024-08-29
AR112482A1 (es) 2019-10-30
ES2931054T3 (es) 2022-12-23

Similar Documents

Publication Publication Date Title
AU2023206175B2 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
TWI869336B (zh) 經典型Fabry氏病患者之治療
JP7755929B2 (ja) ファブリー病患者における心臓機能の強化及び／または安定化方法
JP7680356B2 (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
CA3090499C (en) Use of migalastat for the treatment of patients with classic fabry disease
TW201907921A (zh) 治療ert初治的和已經歷ert的患者中之法布瑞氏症
HK40128496A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
BR112020003974B1 (pt) Métodos para intensificar e/ou estabilizar função cardíaca em pacientes com doença de fabry